CTLA4 and hepatocellular carcinoma: For instance, Belinostat (PDX-101) exhibited tumor stabilization and generally well-tolerated in phase I/II study (NCT00321594).463 Belinostat also achieved complete tumor rejection in a murine HCC model when combined with CTLA-4 and PD-1 blockades.464 Another HDACi tefinostat was assessed in phase I/II clinical test (NCT02759601).